Nebilet (Nebivolol)

Nebivolol, the active ingredient in Nebilet, is a selective β1‑adrenergic receptor antagonist (beta‑blocker) presented as a tablet for oral use. It is used to manage hypertension and chronic heart failure in adult patients.

GNH USA supplies Nebilet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards, provides regulatory documentation for global distribution, and offers both bulk and retail orders manufactured under GMP conditions.

Nebivolol is indicated for cardiovascular conditions that involve elevated blood pressure or impaired cardiac function.

- Hypertension: reduces systolic and diastolic blood pressure, improving vascular control. - Chronic heart failure: enhances left‑ventricular ejection and reduces symptoms of fluid overload.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or general tiredness. - Nasal congestion or mild upper‑respiratory irritation.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to syncope. - Bronchospasm or worsening of asthma symptoms. - Allergic reactions such as rash, angioedema, or anaphylaxis.

When prescribing Nebivolol, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate heart rate and blood pressure before initiation. - Concomitant beta‑blocker therapy: avoid additive bradycardia. - Renal or hepatic impairment: adjust dose or monitor closely. - Diabetes mellitus: monitor blood glucose as beta‑blockers may mask hypoglycaemia symptoms. - Pregnancy and lactation: use only if potential benefit justifies potential risk; safety data are limited. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Other beta‑blockers: risk of excessive bradycardia and hypotension. - Calcium‑channel blockers (verapamil, diltiazem): may potentiate AV‑node slowing. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): increase nebivolol plasma levels. - Severe bradyarrhythmias: co‑administration can exacerbate conduction disturbances.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, requiring blood pressure checks. - ACE inhibitors or ARBs: combined therapy can lead to additive blood pressure reduction. - NSAIDs: may blunt antihypertensive response, necessitating dose adjustments.